OncoMatch/Clinical Trials/NCT07120282
Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Is NCT07120282 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tislelizumab 400 mg iv, q6w, for up to 1 year for pts in intervention group for lung cancer (nsclc).
Treatment: Tislelizumab 400 mg iv, q6w, for up to 1 year for pts in intervention group — A Randomized, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
No EGFR/ALK sensitive mutations
Required: ALK wild-type
No EGFR/ALK sensitive mutations
Required: PD-L1 (CD274) expression ≥1% (≥1%)
PD-L1 expression >=1%
Disease stage
Required: Stage I (AJCC 9th edition)
stage I non - small cell lung cancer (AJCC 9th edition), with tumor size 2cm <= T <=4cm
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumour therapy
Any previous treatment for current lung cancer, including radiotherapy and systemic anti-tumour therapies (chemotherapy, immunotherapy, targeted therapy, anti-angiogenesis therapy, etc.)
Cannot have received: chest radiotherapy
Prior chest radiotherapy (including lung, oesophageal, mediastinal, or breast cancer)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify